Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a trailblazing clinical-stage biotherapeutics company focused on revolutionizing drug delivery through its proprietary platform technology. The company's main innovation, the RaniPill capsule, aims to transform the administration of biologics by making it possible to deliver these typically injectable drugs orally. This groundbreaking approach offers a convenient alternative to patients who frequently endure painful subcutaneous or intravenous injections.
The RaniPill technology has been designed to handle various drug substances, including antibodies, proteins, peptides, and oligonucleotides. Among its key advancements, Rani Therapeutics has introduced the RaniPill HC, a high-capacity capsule that can deliver drug payloads up to 200 microliters in liquid form with high bioavailability. This novel capsule has shown promising results in preclinical studies, demonstrating high reliability and the potential to mimic parenteral drug administration.
Rani Therapeutics has successfully conducted multiple preclinical and clinical trials to evaluate the safety, tolerability, and bioavailability of the RaniPill technology. Significant progress includes the development of two RaniPill capsules: RaniPill GO and RaniPill HC. These trials have validated the platform's ability to convert injectable biologics into oral formats, paving the way for further clinical advancements.
Recently, Rani Therapeutics reported its preliminary consolidated financial results for the third quarter ending September 30, 2023. The company is strategically prioritizing its RT-102 and RT-111 programs while advancing the RaniPill HC towards Phase 1 clinical readiness by the second half of 2024. The company expects to initiate the Phase 2 study of RT-102 in 2023 and aims to achieve key milestones that extend its operational cash runway into 2025.
Looking ahead, Rani Therapeutics continues to focus on expanding its manufacturing capabilities to support scaling and potential partnering opportunities. The company remains committed to its vision of making oral biologics a reality across various therapeutic indications, driving significant value for patients, healthcare providers, and shareholders.
Rani Therapeutics (NASDAQ: RANI) reported Q3 2024 financial results and corporate updates. The company completed two equity offerings raising $20.0 million in gross proceeds, extending cash runway into Q3 2025. Cash position was $30.4 million as of September 30, 2024. Q3 net loss decreased to $12.7 million from $18.3 million year-over-year. R&D expenses decreased to $6.2 million from $11.2 million, while G&A expenses reduced to $5.6 million from $6.6 million. The company announced new preclinical data supporting transenteric delivery of GLP-1 incretin triagonist and plans to initiate Phase 1 trial of RT-114 for obesity treatment in 2025.
Rani Therapeutics Holdings (Nasdaq: RANI), a clinical-stage biotherapeutics company, will participate in three upcoming investor conferences.
The company's management team will attend the UBS Global Healthcare Conference at Terranea Resort, Rancho Palos Verdes, CA on November 14, 2024, at 10:15am PT, the Stifel Healthcare Conference at Lotte New York Palace Hotel, New York, NY on November 18, 2024, at 4:10pm ET, and the 7th Annual Evercore ISI HealthCONx Conference at The Loews Coral Gables Hotel, Coral Gables, FL on December 4, 2024, at 12:55pm ET.
Each event will feature a fireside chat and 1x1 meetings. Interested parties can register and access live webcasts via the “Events” section of the Rani Therapeutics website. Webcast replays will be available post-event.
Rani Therapeutics Holdings (Nasdaq: RANI) has announced a $10.0 million registered direct offering of its Class A common stock and warrants. The company will sell 3,000,000 shares of common stock and pre-funded warrants for 333,333 shares, along with Series C common warrants for up to 3,333,333 shares. Each share or pre-funded warrant is priced at $3.00, bundled with a Series C warrant. The Series C warrants have a $3.00 exercise price and a 5-year expiration. Rani will also cancel all outstanding Series A warrants issued on July 22, 2024. Maxim Group is the sole placement agent, with the offering expected to close around October 16, 2024. The proceeds will be used to support Rani's clinical-stage biotherapeutics work on oral delivery of biologics and drugs.
Rani Therapeutics, a Nasdaq-listed clinical-stage biotherapeutics company (RANI), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company, which focuses on oral delivery of biologics and drugs, will be represented by CEO Talat Imran and CFO Svai Sanford in a fireside chat.
The event is scheduled for Thursday, October 17, 2024, from 11:30 am to 12:00 pm E.T. in Track 2. Interested parties can access the live webcast of the conference through a provided registration link. This participation highlights Rani Therapeutics' engagement with the investment community and its commitment to sharing insights about its innovative approach to drug delivery.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company focusing on oral delivery of biologics and drugs, has announced its participation in two major investor conferences in September 2024. The company will be present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10 and the 2024 Cantor Global Healthcare Conference on September 18, both in New York City.
CEO Talat Imran will represent Rani at both events, delivering a company presentation at the H.C. Wainwright conference and participating in a fireside chat at the Cantor conference. Both events will also include one-on-one investor meetings. Interested parties can access live webcasts of these presentations through the 'Events' section of Rani Therapeutics' website, with replays available after the events conclude.
Rani Therapeutics (Nasdaq: RANI) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Partnership with ProGen to develop RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, with Phase 1 study expected in 2025.
2. Completed equity offering with gross proceeds of $10.0 million.
3. Presented clinical and preclinical data on oral delivery of ustekinumab biosimilar via RaniPill® Capsule at DDW 2024.
4. Q2 2024 financials: Cash and equivalents at $30.9 million, R&D expenses decreased to $6.1 million, G&A expenses decreased to $6.4 million, net loss reduced to $13.4 million.
5. ProGen presented positive Phase 1 data on PG-102 (GLP-1/GLP-2 dual agonist) at ADA 2024 conference.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company focusing on oral delivery of biologics and drugs, has announced its participation in two upcoming investor conferences in August 2024. The company will attend the BTIG Virtual Biotechnology Conference on August 5th-6th, participating in one-on-one investor meetings. Additionally, Rani will present at the Canaccord 44th Annual Growth Conference in Boston on August 13th at 3:30 PM ET, featuring a company presentation by CEO Talat Imran and investor meetings.
Interested parties can access live webcasts of these events through the 'Events' section of Rani Therapeutics' website. Webcast replays will be available after the presentations conclude.
Rani Therapeutics Holdings (Nasdaq: RANI), a clinical-stage biotherapeutics company, has announced a $10.0 million registered direct offering. The offering includes 2,800,000 shares of Class A common stock and pre-funded warrants for 446,753 shares, along with Series A and B common warrants. Each share or pre-funded warrant is sold with one Series A and one Series B warrant at $3.08. The warrants have an exercise price of $3.08 and will be exercisable after 6 months. Series A warrants expire in 18 months, while Series B warrants expire in 5.5 years. Maxim Group is the sole placement agent. The offering is expected to close around July 23, 2024, subject to customary conditions.
Rani Therapeutics announced a partnership with ProGen to develop RT-114, an oral obesity treatment using RaniPill® capsules and ProGen's dual agonist, PG-102. The collaboration features a 50/50 cost and revenue share, with Rani leading development in the US, Europe, Canada, and Australia, while ProGen heads efforts elsewhere. The RT-114 program aims to offer a weekly oral dose, potentially improving patient adherence and therapeutic effects. Previous clinical studies of both the RaniPill® platform and PG-102 have shown promising results in bioavailability and safety profiles.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, announced participation in two investor conferences in May 2024. The H.C. Wainwright 2nd Annual BioConnect Investor Conference will be held on May 20th at Nasdaq Headquarters, New York City, featuring a fireside chat and 1x1 investor meetings with CEO Talat Imran. The UBS Spring Biotech Conference will take place on May 21st at UBS, New York City, consisting of 1x1 investor meetings. Live webcast for the H.C. Wainright Conference will be available on Rani's website.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
What is Rani Therapeutics Holdings, Inc.?
What is the RaniPill capsule?
What drugs can the RaniPill capsule deliver?
What is the difference between RaniPill GO and RaniPill HC?
What recent achievements has Rani Therapeutics made?
What are Rani Therapeutics' future plans?
How have RaniPill capsules performed in clinical trials?
What are the benefits of the RaniPill technology?
How does Rani Therapeutics plan to scale its manufacturing?
Where can I find more information about Rani Therapeutics?
